Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …

Malignant transformation is characterized by dysregulation of diverse cellular processes that
have been the subject of detailed genetic, biochemical, and structural studies, but only …

Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective
therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism …

Sequencing of cell-free DNA in the blood of cancer patients (liquid biopsy) provides
attractive opportunities for early diagnosis, assessment of treatment response, and minimally …

Cancer is the leading disease-related cause of death in children in developed countries.
Arising in the context of actively growing tissues, childhood cancers are fundamentally …

Summary Histone H3. 3 glycine 34 to arginine/valine (G34R/V) mutations drive deadly
gliomas and show exquisite regional and temporal specificity, suggesting a developmental …

Posterior fossa type A (PFA) ependymomas exhibit very low H3K27 methylation and express
high levels of EZHIP (Enhancer of Zeste Homologs Inhibitory Protein, also termed …

Summary H3K27M diffuse intrinsic pontine gliomas (DIPGs) are fatal and lack treatments.
They mainly harbor H3. 3K27M mutations resulting in H3K27me3 reduction. Integrated …

Diffuse midline gliomas and posterior fossa type A ependymomas contain the recurrent
histone H3 lysine 27 (H3 K27M) mutation and express the H3 K27M-mimic EZHIP (CXorf67) …

Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …